Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

Age is a strong prognostic factor in multiple myeloma. The overall survival is shorter in patients older than 66 years, and even shorter in those older than 75 years. Whether age is also a prognostic parameter in patients younger than 66 years treated homogeneously with intensive approaches is unkno...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Chretien, Marie-Lorraine, Hebraud, Benjamin, Cances-Lauwers, Valérie, Hulin, Cyrille, Marit, Gerald, Leleu, Xavier, Karlin, Lionel, Roussel, Murielle, Stoppa, Anne-Marie, Guilhot, Francois, Lamy, Thierry, Garderet, Laurent, Pegourie, Brigitte, Dib, Mamoun, Sebban, Catherine, Lenain, Pascal, Brechignac, Sabine, Royer, Bruno, Wetterwald, Marc, Legros, Laurence, Orsini-Piocelle, Frédérique, Voillat, Laurent, Delbrel, Xavier, Caillot, Denis, Macro, Margaret, Facon, Thierry, Attal, Michel, Moreau, Philippe, Avet-Loiseau, Hervé, Corre, Jill
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Ferrata Storti Foundation 2014
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4077086/
https://ncbi.nlm.nih.gov/pubmed/24727820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.098608
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia